Nevanimibe hydrochloride is an investigational compound primarily studied for the treatment of congenital adrenal hyperplasia (CAH), a genetic disorder affecting the adrenal glands. It works by inhibiting acyl-CoA:cholesterol acyltransferase 1 (ACAT1), an enzyme involved in steroidogenesis, thereby helping to manage hormone imbalances by reducing excess androgen and cortisol production. It also shows potential in clinical research for Cushing's syndrome, a condition caused by excessive cortisol levels. As a research reagent, it is used in preclinical and clinical studies to evaluate its efficacy and safety in endocrine disorders.